Canada markets closed

Glenmark Pharmaceuticals Limited (GLENMARK.BO)

BSE - BSE Real Time Price. Currency in INR
Add to watchlist
1,230.65+9.50 (+0.78%)
At close: 03:29PM IST
Currency in INR

Valuation Measures4

Market Cap (intraday) 347.27B
Enterprise Value 341.25B
Trailing P/E N/A
Forward P/E 14.90
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)2.98
Price/Book (mrq)4.43
Enterprise Value/Revenue 2.93
Enterprise Value/EBITDA 28.84

Trading Information

Stock Price History

Beta (5Y Monthly) 0.83
52-Week Change 378.61%
S&P500 52-Week Change 322.55%
52 Week High 31,264.50
52 Week Low 3662.35
50-Day Moving Average 31,114.73
200-Day Moving Average 3918.96

Share Statistics

Avg Vol (3 month) 322.65k
Avg Vol (10 day) 311.71k
Shares Outstanding 5282.19M
Implied Shares Outstanding 6283.37M
Float 8138.16M
% Held by Insiders 150.97%
% Held by Institutions 126.14%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 42.5
Forward Annual Dividend Yield 40.20%
Trailing Annual Dividend Rate 32.50
Trailing Annual Dividend Yield 30.20%
5 Year Average Dividend Yield 40.49
Payout Ratio 427.72%
Dividend Date 3N/A
Ex-Dividend Date 4Sept 18, 2023
Last Split Factor 22:1
Last Split Date 3Sept 10, 2007

Financial Highlights

Fiscal Year

Fiscal Year Ends Mar 31, 2024
Most Recent Quarter (mrq)Mar 31, 2024

Profitability

Profit Margin -12.71%
Operating Margin (ttm)11.52%

Management Effectiveness

Return on Assets (ttm)2.27%
Return on Equity (ttm)-20.70%

Income Statement

Revenue (ttm)118.13B
Revenue Per Share (ttm)418.66
Quarterly Revenue Growth (yoy)-9.20%
Gross Profit (ttm)N/A
EBITDA 12.44B
Net Income Avi to Common (ttm)-18.99B
Diluted EPS (ttm)-67.32
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)16.59B
Total Cash Per Share (mrq)58.8
Total Debt (mrq)12.31B
Total Debt/Equity (mrq)15.69%
Current Ratio (mrq)1.28
Book Value Per Share (mrq)278.09

Cash Flow Statement

Operating Cash Flow (ttm)-2.65B
Levered Free Cash Flow (ttm)27.26B